Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.

Abstract	A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy. Two years later C-erbB2-positive IBC was diagnosed in the right breast, and was treated with mastectomy and radiotherapy. Two years later skin metastases appeared, and trastuzumab was started initially as monotherapy, and later with paclitaxel and capecitabine. More than 12 years after diagnosis and 7 years after trastuzumab was started, the patient remains in complete clinical remission on trastuzumab and capecitabine.
Authors	Alicia Lázaro, Javier Casinello, Almudena Amorós, Miriam Heredia, Ana López-Alfonso
Journal	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (Clin Transl Oncol) Vol. 10 Issue 9 Pg. 587-90 (Sep 2008) ISSN: 1699-048X [Print] Italy
PMID	18796377 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Deoxycytidine Capecitabine Receptor, ErbB-2 Trastuzumab Paclitaxel Cisplatin Fluorouracil
Topics	Adult Antibodies, Monoclonal (administration & dosage) Antibodies, Monoclonal, Humanized Antineoplastic Agents (adverse effects) Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Breast Neoplasms (drug therapy, metabolism, pathology) Capecitabine Carcinoma, Ductal, Breast (drug therapy, metabolism, secondary) Cisplatin (adverse effects) Deoxycytidine (administration & dosage, analogs & derivatives) Female Fluorouracil (administration & dosage, analogs & derivatives) Humans Mastectomy Neoplasms, Second Primary Paclitaxel (administration & dosage) Receptor, ErbB-2 (metabolism) Remission Induction Skin Neoplasms (drug therapy, mortality, secondary) Survival Rate Trastuzumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!